Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 423

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1
Chunk 423
---
 thereunto duly authorized.AGIOS PHARMACEUTICALS, INC.February 13, 2025By:/s/ Brian GoffBrian GoffChief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.SignatureTitleDate/s/ Brian GoffChief Executive Officer(Principal executive officer)February 13, 2025Brian Goff/s/ Cecilia JonesChief Financial Officer(Principal financial officer)February 13, 2025Cecilia Jones/s/ T.J. WashburnVice President, Controller(Principal accounting officer)February 13, 2025T.J. Washburn/s/ Jacqualyn A. FouseChair of the Board of DirectorsFebruary 13, 2025Jacqualyn A. Fouse, Ph.D./s/ Rahul BallalDirectorFebruary 13, 2025Rahul Ballal, Ph.D./s/ Jeffrey CapelloDirectorFebruary 13, 2025Jeffrey Capello/s/ Kaye FosterDirectorFebruary 13, 2025Kaye Foster/s/ Maykin HoDirectorFebruary 13, 2025Maykin Ho, Ph.D./s/ Catherine OwenDirectorFebruary 13, 2025Catherine Owen/s/ David ScaddenDirectorFebruary 13, 2025David Scadden, M.D./s/ David P. SchenkeinDirectorFebruary 13, 2025David P. Schenkein, M.D./s/ Cynthia SmithDirectorFebruary 13, 2025Cynthia Smith

90

Agios Pharmaceuticals, Inc.

Index to Consolidated Financial StatementsReport of Independent Registered Public Accounting Firm (PCAOB ID 238)2Consolidated Balance Sheets4Consolidated Statements of Operations5Consolidated Statements of Comprehensive Income (Loss)6Consolidated Statements of Stockholders’ Equity7Consolidated Statements of Cash Flows8Notes to Consolidated Financial Statements9

F-1

 Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Agios Pharmaceuticals, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Agios Pharmaceuticals, Inc. and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated